509 related articles for article (PubMed ID: 28271239)
1. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
[TBL] [Abstract][Full Text] [Related]
2. Two Phase 1, Open-Label, Mass Balance Studies to Determine the Pharmacokinetics of
Townsend R; Kato K; Hale C; Kowalski D; Lademacher C; Yamazaki T; Akhtar S; Desai A
Clin Pharmacol Drug Dev; 2018 Feb; 7(2):207-216. PubMed ID: 28750160
[TBL] [Abstract][Full Text] [Related]
3. Effect of mild and moderate liver disease on the pharmacokinetics of isavuconazole after intravenous and oral administration of a single dose of the prodrug BAL8557.
Schmitt-Hoffmann A; Roos B; Spickermann J; Heep M; Peterfaí E; Edwards DJ; Stoeckel K
Antimicrob Agents Chemother; 2009 Nov; 53(11):4885-90. PubMed ID: 19667286
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Interaction Between Isavuconazole and a Fixed-Dose Combination of Lopinavir 400 mg/Ritonavir 100 mg in Healthy Subjects.
Yamazaki T; Desai A; Han D; Kato K; Kowalski D; Akhtar S; Lademacher C; Kovanda L; Townsend R
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):93-101. PubMed ID: 27273248
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic Analysis of Isavuconazole Against Aspergillus spp. and Candida spp. in Healthy Subjects and Patients With Hepatic or Renal Impairment by Monte Carlo Simulation.
Zheng X; Xu G; Zhu L; Fang L; Zhang Y; Ding H; Tong Y; Sun J; Huang P
J Clin Pharmacol; 2018 Oct; 58(10):1266-1273. PubMed ID: 29762861
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic and Pharmacodynamic Evaluation of the Drug-Drug Interaction Between Isavuconazole and Warfarin in Healthy Subjects.
Desai A; Yamazaki T; Dietz AJ; Kowalski D; Lademacher C; Pearlman H; Akhtar S; Townsend R
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):86-92. PubMed ID: 27278712
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis.
Mistry GC; Majumdar AK; Swan S; Sica D; Fisher A; Xu Y; Hesney M; Xi L; Wagner JA; Deutsch PJ
J Clin Pharmacol; 2006 Oct; 46(10):1128-38. PubMed ID: 16988201
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH.
Schmitt-Hoffmann A; Desai A; Kowalski D; Pearlman H; Yamazaki T; Townsend R
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):572-80. PubMed ID: 27345284
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects.
O'Donnell J; Preston RA; Mamikonyan G; Stone E; Isaacs R
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31307978
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
[TBL] [Abstract][Full Text] [Related]
11. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study.
Stangier J; Rathgen K; Stähle H; Mazur D
Clin Pharmacokinet; 2010 Apr; 49(4):259-68. PubMed ID: 20214409
[TBL] [Abstract][Full Text] [Related]
12. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults.
Townsend R; Dietz A; Hale C; Akhtar S; Kowalski D; Lademacher C; Lasseter K; Pearlman H; Rammelsberg D; Schmitt-Hoffmann A; Yamazaki T; Desai A
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):44-53. PubMed ID: 27273461
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
.
Gardin A; Dodman A; Kalluri S; Neelakantham S; Tan X; Legangneux E; Shakeri-Nejad K
Int J Clin Pharmacol Ther; 2017 Jan; 55(1):54-65. PubMed ID: 27841151
[TBL] [Abstract][Full Text] [Related]
16. Population Pharmacokinetics of Isavuconazole in Subjects with Mild or Moderate Hepatic Impairment.
Desai A; Schmitt-Hoffmann AH; Mujais S; Townsend R
Antimicrob Agents Chemother; 2016 May; 60(5):3025-31. PubMed ID: 26953193
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and Methadone in Healthy Subjects.
Yamazaki T; Desai A; Goldwater R; Han D; Howieson C; Akhtar S; Kowalski D; Lademacher C; Pearlman H; Rammelsberg D; Townsend R
Clin Pharmacol Drug Dev; 2017 Jan; 6(1):54-65. PubMed ID: 27273149
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions.
Bergmann F; Wölfl-Duchek M; Jorda A; Al Jalali V; Leutzendorff A; Sanz-Codina M; Gompelmann D; Trimmel K; Weber M; Eberl S; Van Os W; Minichmayr IK; Reiter B; Stimpfl T; Idzko M; Zeitlinger M
J Antimicrob Chemother; 2024 May; 79(5):1169-1175. PubMed ID: 38546795
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of topiramate in patients with renal impairment, end-stage renal disease undergoing hemodialysis, or hepatic impairment.
Manitpisitkul P; Curtin CR; Shalayda K; Wang SS; Ford L; Heald DL
Epilepsy Res; 2014 Jul; 108(5):891-901. PubMed ID: 24725807
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment.
Worboys PD; Wong SL; Barriere SL
Eur J Clin Pharmacol; 2015 Jun; 71(6):707-714. PubMed ID: 25939708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
